ARTICLE / VIDEO
2023 IP Outlook: The Latest in SEP Licensing
February 2, 2023
Read time: 5 min

The uncertainty surrounding standard essential patent (SEP) licensing persisted in 2022 and shows little sign of clearing in 2023. SEPs must be licensed to technology implementers on fair, reasonable and nondiscriminatory (FRAND) terms. Because there is no formal definition of FRAND terms, however, legal decisions involving FRAND have historically been determined by courts and non-governmental standard-setting organizations (SSOs). Disputes are frequent—especially between patent owners and technology implementers—and are becoming even more so as advanced wireless technologies such as 5G and WiFi 6 proliferate.
Various countries—including the United States—and SSOs developed new policies in 2022 to balance the interests of patent owners and licensees, but there is still a dearth of broad-ranging regulation. The United States still has no official policy on the appropriate remedies in an SEP/FRAND dispute. This hands-off approach introduces substantial uncertainty for parties litigating 5G patents in the United States.
Looking ahead: The US Department of Justice (DOJ) pledged to review conduct by patent holders and implementers on a case-by-case basis “to determine if either party is engaging in practices that result in the anticompetitive use of market power or other abusive processes that harm competition,” but it remains to be seen how involved the DOJ will actually be.
Global policy for SEP disputes is similarly unsettled, as many countries are also assessing their policies.
- Europe is a particularly advantageous litigation venue for patent holders. For example, several injunctions issued in Germany in 2022 against well-known companies, including Huawei, Ericsson and Ford. The European Union is currently assessing a new framework for SEP regulation, with a focus on transparency and efficiency in minimizing licensing disputes, but it’s unclear when and if the EU will release any proposals. The United Kingdom is also reviewing its SEP policy.
- In late 2021, China’s highest court ruled that it could set the terms of global FRAND rates under certain circumstances, including adjudication of a dispute involving a foreign party if the dispute has an “appropriate connection” with China. An “appropriate connection” can be established if China is the country where the defendant is located, where the patent is to be enforced, or where a contract is signed or performed. This ruling may open the door to more patent holders filing or threatening to file SEP disputes in China.
- The Chinese decision followed on the heels of a UK court finding that the United Kingdom had jurisdiction to hear global disputes under contract law since a patent owner’s FRAND obligation stems from a contractual commitment made to SSOs, and because national courts may adjudicate disputes relating to those obligations.
Looking ahead: While Europe is one of the most popular venues for SEP disputes, South America might become a more popular venue for SEP litigation. Ericsson recently won a preliminary injunction against Apple in Colombia. It is unlikely that patent holders will turn to courts in South America to establish rates, but they may well use the injunction to accelerate licensing negotiations.
On the policy front, the Institute of Electrical and Electronics Engineers announced in September 2022 that it was removing limits on patent owners’ ability to seek injunctions.
Looking ahead: This appears to be another win for patent owners and may provide further leverage during licensing negotiations.
In SEP-related litigation, 2022 saw the resolution of a high-profile dispute over whether a patent owner was required to license SEP patents to specific implementers in the supply chain. This issue has been a theme in the United States and beyond, as SEP licensors (particularly those in 3G, 4G and 5G spaces) tend to offer licenses solely to end-product manufacturers and not to subcomponent manufacturers or other supply chain entities. In Continental Automotive Systems v. Avanci, the US Court of Appeals for the Fifth Circuit found that Continental did not have Article III standing to bring an antitrust lawsuit against Avanci after Avanci refused a license to Continental.
Looking ahead: The decision confirms that patent owners have significant discretion in developing their licensing programs and deciding to whom in the supply chain they want to license. SEPs are thus likely to continue licensing the end-manufacture of products since those agreements likely offer the highest license payments.

2023 IP Outlook: Improper Inventorship in US Patent Litigations
ARTICLE / VIDEO
2023 IP Outlook: Improper Inventorship in US Patent Litigations
February 2, 2023
Read time: 4 min

Inventorship issues can have serious implications in patent litigation, leading to invalidation or unenforceability of the patent at issue, as seen in several notable 2022 cases. In the coming year, patent owners should take steps to minimize risks related to improper inventorship challenges.
Improper inventorship typically arises in one or more of the following situations:
- Nonjoinder – failing to name an inventor
- Misjoinder – naming an incorrect inventor
- Derivation – a named inventor deriving the invention from another unnamed inventor
A patentee can avoid invalidity by correcting inventorship under Section 256 in most circumstances. To correct inventorship, the patentee must understand the legal definition of an inventor in the US:
- An inventor is the individual (or if a joint invention, the individuals) who invented or discovered the subject matter of the invention. Joint inventor contributions can be unequal, and contribution to one claim is sufficient.
- An inventor must contribute to the conception of the invention; mere reduction-to-practice is not enough. For example, co-authorship on a peer-reviewed publication by itself is insufficient to meet the inventive contribution requirement, but can be used as support of inventorship.
- In 2022, the US Court of Appeals for the Federal Circuit held that the Patent Act requires inventors to be natural persons—“that is, human beings”—and not an artificial intelligence (AI) system.
Looking ahead: Companies in industries that rely heavily on AI should ensure that humans are involved in the creation and/or development of intellectual property because a machine or AI will not qualify as an inventor in a US patent application.
Because the America Invents Act Section 256 removed the “without deceptive intent” requirement to correct inventorship, inventorship errors—whether intentional or not—can be corrected under Section 256. But inventorship issues made with deceptive intent can still cause a patent to be held unenforceable under a claim of inequitable conduct if the challenging party shows with clear and convincing evidence that the patent applicant withheld or misrepresented “but-for” material information and acted with specific intent to deceive the US Patent and Trademark Office.
Looking ahead: Patent owners can take proactive steps to mitigate risks associated with improper inventorship:
- Secure patent ownership rights through employee, contractor and/or consultant agreements that contain present assignment language. Courts have held that sufficient assignment language includes “will assign and does hereby assign,” instead of a mere statement that the intellectual property “shall be the property” of the entity. Consider confirmatory assignment agreements if there is uncertainty about the proper assignment language in your current agreements.
- Perform regular audits of key intellectual property and assess inventorship for each patent application, particularly for complex patent families that include continuations-in-part.
- Ensure that proper intellectual property ownership agreements are in place for research and development projects involving joint research or collaboration with third parties.
- Conduct searches of publications for all individuals who participate in a project that may involve the creation or development of intellectual property. A publication’s authors may be different than the individuals named on a patent with overlapping subject matter, which could lead to improper inventorship challenges.
- Protect privilege during diligence relating to inventorship to minimize exposure during discovery and depositions if inventorship is ever litigated.

2023 IP Outlook: Patent Decisions Affecting Pharma and Biotech Companies
ARTICLE / VIDEO
2023 IP Outlook: Patent Decisions Affecting Pharma and Biotech Companies
February 2, 2023
Read time: 5 min

The past year brought many developments in the life sciences patent legal space. Three decisions in particular hold potential ramifications for drug makers and patent holders in 2023. This year, the Supreme Court of the United States is also expected to consider standards patents claiming a genus must meet to withstand a validity challenge under Section 112—a ruling that could have a significant impact on patent holders in the biotech industry.
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA
In a notable 2022 ruling, the US Court of Appeals for the Federal Circuit denied Teva’s petition for en banc review of a decision finding that, despite Teva’s adherence to skinny labeling rules, its label induced infringement. The ruling suggested that equitable estoppel was the appropriate vehicle for considering whether the branded drug manufacturer’s representations to the FDA should prevent it from prevailing. Teva had explicitly excluded any reference to GlaxoSmithKline’s patented indication but was still found liable for infringement. However, the Court did suggest that Teva may be successful in its still-pending equitable estoppel defense against GlaxoSmithKline’s misrepresentations to the US Food and Drug Administration (FDA).
Looking ahead: Innovator pharmaceutical companies can expect that their generic competitors will be more cautious in relying on statements to the FDA. However, innovators themselves need to be mindful of potential liability for statements made to the FDA that could be at odds with their patent enforcement activities.
Niazi Licensing Corporation v. St Jude Medical S.C., Inc.
The Federal Circuit also overturned a district court determination that claim terms of degree, such as “resilient” and “pliable,” were necessarily indefinite. The Court found that the patent’s written description and prosecution history provided sufficient context to allow a skilled artisan to determine the scope of the claims with reasonable certainty, consistent with the established requirement under Nautilus that claims must provide “objective boundaries.”
Looking ahead: This ruling bodes well for patent holders that were previously concerned their patents might be found invalid due to indefiniteness, allowing them to more confidently assert their patent rights.
Mayor and City Council of Baltimore v. AbbVie Inc.
The Seventh Circuit found that AbbVie was not in violation of the Sherman Antitrust Act, despite owning 132 patents around the drug Humira—a so-called “patent thicket.” The Court held that in order to demonstrate a violation, the plaintiffs must establish actual harm to competition or show that all 132 patents were invalid.
Looking ahead: This ruling may encourage patent holders to develop similar “patent thickets” and use them to establish market dominance without compromising profits or risking antitrust liability.
Amgen Inc., et al. v. Sanofi, et al.
The Supreme Court recently agreed to consider the question of how much a patent must disclose to meet the enablement requirement under Section 112 for genus claims. The Supreme Court will weigh whether it is sufficient for the specification to simply teach those skilled in the art to “make and use” the claimed invention, or if it must meet the higher standard imposed by the Federal Circuit, which requires that the patent equip those skilled in the art to “reach the full scope of claimed embodiments” without undue experimentation.
Looking ahead: The Supreme Court’s opinion could affect many patent holders, and innovation generally, in the biotech industry and other industries by determining standards patents claiming a genus must meet to withstand a validity challenge under Section 112. Watch for the Supreme Court’s ruling and its potential effects on patent litigation in the year to come.

2023 IP Outlook: Trends in the Western District of Texas
ARTICLE / VIDEO
2023 IP Outlook: Trends in the Western District of Texas
February 2, 2023
Read time: 5 min

Over the past year, two developments infiltrated the Western District of Texas (WDTX) which may decrease the success of venue transfers and keep case volume steady in 2023. These developments could also give plaintiffs more control over where litigation takes place, including more control over having a case tried before Judge Alan Albright in the Waco Division of the WDTX.
The US Court of Appeals for the Federal Circuit’s rate for grant of mandamus petitions on venue-related motions slowed down.
In recent years, the Federal Circuit has been active in hearing mandamus petitions filed under §1404(a) regarding the convenient venue provision, which have most frequently come from defendants challenging transfer denials from the Waco Division. In 2021, the Federal Circuit took a close look at the motion to transfer denials in the Waco Division of the WDTX, granting 48% of mandamus petitions. In 2022, we saw the success rate for mandamus petitions reduced to 40%. While the mandamus success rate declined, transfer motions granted in the Waco Division increased from 35% in 2021 to 58% in 2022.
A recent decision by the US Court of Appeals for the Fifth Circuit has breathed new life into certain factors considered in the §1404(a) analysis that may slow or reverse these trends.
In In re Planned Parenthood Fedn. Of Am., Inc., the Fifth Circuit denied a mandamus petition where the movant sought to transfer the case from the Northern District of Texas in Amarillo to the WDTX in Austin. In denying the petition, the Fifth Circuit noted the following grounds as relevant considerations:
- The Fifth Circuit found no abuse of discretion where the district court judge noted his familiarity with the law as one factor for keeping the case.
- The Fifth Circuit also explained that the location of evidence factor can be important, but not where the “vast majority of the evidence [is] electronic, and therefore equally accessible in either forum.”
- The Fifth Circuit found no abuse of discretion where the district court judge took into account the low cost of staying in hotels and eating in Amarillo as compared to Austin.
Looking ahead: If the Federal Circuit considers this opinion by the Fifth Circuit, as it should in a venue analysis, the decision could decrease the trend of mandamus grants for venue-related decisions coming out of the WDTX.
In 2022, WDTX Chief Judge issued orders about random assignment and the reassignment of patent cases.
Former-Chief Judge Orlando L. Garcia issued an order in July 2022 that called for random assignment of patent cases filed in the Waco Division. Newly appointed WDTX Chief Judge Alia Moses has so far kept the random assignment policy for patent cases filed in the Waco Division. Her order, following Judge Garcia’s and effective December 16, 2022, allows for judges to reassign cases to other judges by mutual consent.
Despite the orders requiring random assignment, the WDTX remains the leading venue for patent cases filed across the country with 1-in-5 patent cases being filed in this district.
- Between January 1, 2022, to July 25, 2022 (when the random assignment order issued), 24.6% of all patent cases were filed in the WDTX.
- Since the order issued on July 25, 2022, to present, approximately 20% of all patent cases were filed in the WDTX.
Looking ahead:
- Even though the WDTX may have lost some of its share of patent cases, the district will likely continue to take the lead with respect to the number of patent cases filed in Texas. This is in large part due to the number of businesses that have continued to flock to the Lone Star State, especially in the central Texas region, in the recent past.
- Another contributing factor in this trend is that Delaware—which tends to be another patent-heavy docket—has been closely scrutinizing litigation funders backing patent plaintiffs that may be dissuading patent plaintiffs from flocking to the First State.
- These factors make it likely that many plaintiffs will continue to bring and try their cases in the WDTX.

2023 IP Outlook: Unified Patent Court and Unitary Patent Update
ARTICLE / VIDEO
2023 IP Outlook: Unified Patent Court and Unitary Patent Update
February 2, 2023
Read time: 5 min

Set to open on June 1, 2023, the new Unified Patent Court (UPC) will revolutionize patent enforcement across 17 participating European Union (EU) Member States. The UPC will have exclusive jurisdiction over the new European patents with unitary effect (unitary patents), as well as new and existing national patents obtained through validation of a European patent in participating countries. Companies that hold European patents or conduct business in Europe should prepare for the new system by understanding the UPC’s implications and opportunities.
The UPC will provide streamlined enforcement of patents by issuing infringement and validity decisions, and will provide remedies such as injunctions and damages. Its enforcement will be effective across all participating countries.
Impact: The UPC may reduce the need for parallel national court cases, decreasing costs and complexity and avoiding the possibility of conflicting decisions from different national courts. The UPC aims to provide speedy decisions, with oral hearings within one year of filing an action and a written decision within six weeks of the hearing.
The UPC also provides exciting new opportunities for challenging patents. Currently, a European patent can only be opposed at the European Patent Office (EPO) within nine months of grant. Revocation at the UPC is not subject to that time limit or precluded by a previous EPO opposition.
Impact: Parties can launch an action at the UPC to revoke a European patent that can no longer be opposed at the EPO or that was unsuccessfully opposed at the EPO.
The UPC will have a central division with locations in Paris and Munich, and several local and regional divisions to hear cases at first instance. The UPC’s court of appeal will be located in Luxembourg, and a patent arbitration and mediation center will be shared by Lisbon and Ljubljana. The Court of Justice of the European Union also may be requested to give preliminary rulings on questions of EU law.
Impact: Cases will be decided by a panel of judges from different countries. Judges may be legally qualified, technically qualified, or both.
Owners of existing European patents or pending applications can “opt out” of the UPC’s jurisdiction, but the opt-out will only be effective for a transitional period of up to seven years (with possible extension of up to 14 years). Unitary patents and patents that are already the subject of an action before the UPC cannot be opted out.
When deciding whether to opt out, patent owners should consider how to weigh the benefits of the simplified enforcement procedure against the risk of centralized revocation. For example, patents that are extremely valuable or that seem vulnerable to challenge by a competitor may benefit from opting out. It will be possible to reverse an opt-out during the transition period, but not if the patent is enforced or attacked in national court. If a patent owner reverses an opt-out for a patent, that patent may not be opted out again.
Impact: Parties that wish to opt out should consider filing a request before the UPC opens. Opt-out requests can be filed during the “sunrise period” due to start on March 1, 2023.
Next Steps:
- Review your patent portfolio and decide whether to opt out any patents or patent applications, keeping in mind the imminent sunrise period.
- Consider the centralized enforcement possibilities provided by the UPC.
- Assess potential infringement threats from competitors and consider challenging their patents at the UPC.
To start preparing, visit McDermott’s UPC Resource Center.

2023 IP Outlook: Developments in Trademark and Copyright Process and Procedure
ARTICLE / VIDEO
2023 IP Outlook: Developments in Trademark and Copyright Process and Procedure
February 2, 2023
Read time: 4 min

Throughout 2022, the procedural rules of the US Patent and Trademark Office (PTO) and the newly formed Copyright Claims Board (CCB) underwent several developments. The PTO outlined a new administrative process for addressing fraudulent trademark submissions, shortened the response time for trademark office actions and tested procedural rules for the Trademark Modernization Act. Meanwhile, the US Copyright Office issued new rules that govern CCB procedure. These developments should help businesses obtain intellectual property protection more efficiently in 2023.
Under its new guidelines, the PTO can now sanction suspicious trademark filings based on an investigation triggered by information from examining attorneys, data analytics or internal sources. The PTO appears to be capitalizing on this new power and has already sanctioned three entities, which are controlled by one company and collectively defrauded more than 5,500 trademark applicants.
Looking ahead: This new process aims to protect small entities from exploitation during the filing process and will likely help larger corporations avoid trademark trolls.
In implementing the Trademark Modernization Act, the PTO shortened the response time for office actions from six months to three months, except for post-registration office actions and office actions for Madrid Protocol applications. The change in response time went into effect on December 3, 2022.
Looking ahead: With this change, the trademark application process will be significantly shortened. Businesses can expect to see the registration of their mark happen at a faster pace.
The PTO tested its new procedural rules for expungement and reexamination under the Trademark Modernization Act. Since its implementation in December 2021, the PTO has received more than 130 petitions under these new rules, and at least 50 proceedings have been initiated. The new procedures are significantly less costly than traditional PTO proceedings and, if they continue to operate successfully, offer a cost-effective way to get a quick decision on canceling a mark.
Looking ahead: Corporations can expect to spend less time and money on fighting to cancel unused marks in pursuit of their own registrations.
The Copyright Office also clarified the procedural rules for the CCB, an administrative forum for copyright claims seeking up to $30,000 in damages. The CCB saw significant use in 2022, with at least 150 cases filed. The Copyright Office detailed how companies can designate agents, how libraries can opt out of CCB proceedings, how law students can represent clients in the CCB, and how the CCB will handle cases referred from a district court. These procedural rules were implemented in June 2022 when the CCB began hearing cases.
Looking ahead: Corporations should be aware that although CCB proceedings can be instituted against them, they may opt out and choose to litigate in a federal district court instead.

2023 IP Outlook: Trademark and Copyright Supreme Court Update
ARTICLE / VIDEO
2023 IP Outlook: Trademark and Copyright Supreme Court Update
February 2, 2023
Read time: 5 min

Three interesting intellectual property cases are on the Supreme Court of the United States’ docket in 2023. The Supreme Court’s opinions in these cases could have significant implications for trademark and copyright disputes going forward, so businesses should take note of the rulings when they issue.
VIP Products v. Jack Daniel’s
The Supreme Court’s ruling in this case could put an end to inconsistent treatment of the First Amendment parody defense in trademark law. In the most recent development, the Supreme Court will review the following questions:
- How far does First Amendment protection extend regarding humorous, commercial use of a third-party trademark?
- Can the humorous use of a third-party trademark on a product offered for sale be considered noncommercial use (and therefore evade a dilution claim)?
This is the second time Jack Daniel’s filed a petition for certiorari in connection with this case. The first petition on the same issue was denied by the Supreme Court without comment.
Looking ahead:
- The Supreme Court’s decision in VIP Products v. Jack Daniel’s should clarify the strength—or limitations—of a First Amendment parody defense.
- The decision may open (or close) the door to further litigation for trademark infringement and dilution regarding parody products—particularly if the Court leaves unanswered questions about what qualifies as an expressive work (or not).
- The decision should provide helpful guidance both for parties creating products that parody third-party trademarks and for trademark owners.
Notable cases with similar parody defense issues include Louis Vuitton v. My Other Bag (purses featuring images of Louis Vuitton bags and other designer handbags), Louis Vuitton v. Haute Diggity Dog (Chewy Vuitton dog toys) and Smith v. Wal-Mart Stores, Inc. (WAL*OCAUST products).
Abitron Austria GmbH v. Hetronic International, Inc.
In this case, the Supreme Court’s ruling could resolve a circuit split regarding the correct test for whether the Lanham Act should be applied extraterritorially. In the underlying case on appeal, the US Court of Appeals for the Tenth Circuit largely followed the US Court of Appeals for the First Circuit’s McBee test. Under the test, if the defendant is not a US citizen and its conduct has a substantial effect on US commerce, the court should consider whether the extraterritorial application of the Lanham Act would create a conflict with foreign law. For the first time since the 1950s, the Supreme Court will consider whether the Lanham Act can apply extraterritorially, even to foreign sales that never reached the United States or confused US consumers.
Looking ahead:
- This case is particularly timely given that counterfeit goods continue to be a significant issue for brand owners and the public generally across a broad scope of industries. Even if not intended for the US market, counterfeit goods can make their way into US commerce and to US consumers. The decision may impact a company’s ability to obtain damages for international trademark infringement.
- The Supreme Court’s decision may also provide trademark owners with another tool for tackling the increase of foreign counterfeit goods.
Andy Warhol Foundation for the Visual Arts v. Goldsmith
Touching the states of two of the world’s best-known artists, this case addresses whether Warhol’s Prince Series (a set of 15 prints created from Lynn Goldsmith’s photograph of Prince) qualifies as a transformative work of the original such that the prints are protected via fair use. The case focuses on the distinction between derivative works and transformative works and the scope of the fair use doctrine. If Warhol’s famous Prince Series is a transformative work, then it may be protected under the fair use doctrine. If it is a derivative work, then it may constitute copyright infringement, since the right to make a derivative work is one of the exclusive rights granted to copyright owners.
This distinction is the subject of a split between the US Court of Appeals for the Ninth Circuit and the US Court of Appeals for the Second Circuit. Many influential organizations filed amicus briefs in this case, including the Guggenheim, several Harvard Law School groups, various photographer associations and guilds, and the Recording Industry Association of America.
Looking ahead:
- The implications of this decision could be far-reaching, as any further guidance about where a derivative work ends and a transformative work begins arguably impacts the scope of protection offered under copyright law.
- For example, this case may help clarify whether NFTs (and other types of digital art) are independent works protected via the fair use doctrine or if they require a license from the original copyright holder.

2023 IP Outlook: The Impact of the Metaverse and NFTs on IP Protections
ARTICLE / VIDEO
2023 IP Outlook: The Impact of the Metaverse and NFTs on IP Protections
February 2, 2023
Read time: 6 min

In 2023, we believe that intellectual property issues in relation to the metaverse, blockchain technologies and crypto assets will continue to be an important focus for brand owners and for businesses entering or expanding into this evolving space. Two metaverse and NFT lawsuits took center stage in 2022 and are important to watch in 2023: Hermès’s suit over MetaBirkins NFTs and Nike’s suit against StockX.
Hermès v. Rothschild
Hermès filed a lawsuit against artist Mason Rothschild for his use of the BIRKIN trademarks in connection with his MetaBirkins NFTs, alleging trademark infringement and dilution. Rothschild argued that the claims should be dismissed based on Rogers v. Grimaldi and subsequent case law indicating that digital images of the bags are “art” and receive protection under the First Amendment, but Hermès argued that the sale of NFTs was purely commercial and therefore Rogers was inapplicable.
In May 2022, the US District Court for the Southern District of New York found that Rothschild’s MetaBirkins NFTs were digital images capable of constituting a form of artistic expression, meaning that the images were entitled to First Amendment protection and therefore Rogers applied. However, the court denied Rothschild’s motion to dismiss because Hermès sufficiently alleged that Rothschild’s use of MetaBirkins either has no artistic relevance to the underlying work whatsoever or, even if it has some artistic relevance, it explicitly misleads as to the source or the content of the work. The case is proceeding to trial.
Takeaways (for now):
- Merely attaching an NFT to an otherwise expressive work may not be sufficient to defeat Rogers’ First Amendment protections.
- The Court stated in a footnote that Rogers might not apply “if the NFTs were attached to a digital file of a virtually wearable Birkin handbag, in which case the ‘MetaBirkins’ mark would refer to a non-speech commercial product,” which could have significant implications for the meta commodity industry.
Nike v. StockX
In February 2022, Nike filed a trademark suit after StockX, a company that resells sneakers, announced that it would use NFTs to allow buyers to track ownership of physical products resold on the StockX platform and to confirm authenticity. StockX argued that its use of third-party brands featured in the NFTs was protected under the first sale doctrine. Nike countered that the NFTs were distinct digital products with independent value and that StockX was profiting from Nike’s IP.
Takeaways:
- These issues could shape the IP landscape around NFTs, the legal distinction between NFTs and physical assets, and the use of trademarks in connection with creative works.
- In particular, creators may need to take more precautions when launching NFTs of other products.
Another area to watch in 2023 is the US Patent and Trademark Office’s (PTO’s) handling of metaverse and NFT-related trademark applications. Brands have rushed to the PTO to file trademark applications in relation to metaverse environments and digital assets, including NFTs. The PTO’s review of these applications and approved descriptions to date provide some guidance as to how the PTO may classify these products and services, how “likelihood of confusion” refusals might be issued with respect to digital versus terrestrial products and services, and what makes a mark “merely descriptive” of metaverse-related goods and services.
Takeaways:
- Generally, “virtual goods” appear to be proper to Class 9, but further clarity regarding the nature of the goods may be required (i.e., “virtual goods” alone is too vague).
- For NFTs, the applicant must specify the type of digital item authenticated.
- PTO “likelihood of confusion” assessments include the following:
- Digital trading cards (Class 9) related to physical card games (Class 28)
- Traditional event services in Class 41, presumably encompassing virtual-related events
- Retail store services for virtual clothing goods in virtual worlds (Class 35) related to traditional clothing (Class 25)
- On the issue of descriptiveness, the PTO registered “METAJACKET” in Class 9 for “downloadable virtual goods, namely, articles of clothing, featuring jackets,” but took issue with the mark “CYBERSNEAKER” as descriptive for “downloadable virtual goods” in Class 9.
Looking ahead, businesses may face the following challenges and opportunities:
- Issues enforcing trademark rights with respect to blockchain domain names. Blockchain domain names link to an address on a blockchain and are often used as short-form addresses for sending and receiving crypto assets. Currently, these domains operate outside of the traditional ICANN domain name systems and are not subject to many of the rules and requirements of traditional domain names. The use of brand names in or as blockchain domains can create consumer confusion and may result in the loss of crypto assets due to such confusion. Based on the current system, brands likely will need to choose between attempting to work with certain marketplaces to stop the use or registration of infringing domains, or attempt to secure blockchain domain names quickly, ahead of potential bad-faith users.
- Considerations related to the right of publicity for virtual avatars. The right of publicity refers to a person’s right to control the commercial use of her name, image and likeness. But how does a well-known person stop others from usurping his likeness in virtual environments? And, conversely, if a virtual persona becomes meta-famous, does an individual have rights to protect her avatar’s likeness?
- The US Copyright Office and PTO’s joint study regarding issues of trademark, patent, and copyright law and policy arising from the use of NFTs. While the study is ongoing, its results will likely provide some guidance on the direction of intellectual property laws and protections for NFTs and the metaverse more broadly.

CMS Streamlines Medicare Enrollment and Standardizes Nondiscrimination Language on Newly Renewed Hospital Notices to Beneficiaries
ARTICLE / CLIENT ALERT
CMS Streamlines Medicare Enrollment and Standardizes Nondiscrimination Language on Newly Renewed Hospital Notices to Beneficiaries
February 1, 2023
Read time: 5 min
In late January 2023, the Centers for Medicare and Medicaid Services (CMS) issued two updates relevant to provider and supplier organizations enrolled in Medicare: (1) a redesign to the Provider Enrollment, Chain and Ownership System (PECOS) with several new features intended to ease the initial application and administrative upkeep of Medicare enrollments; and (2) CMS expects providers and suppliers to confirm that their ownership information is consistent for all enrollment records under a particular Tax Identification Number (TIN). CMS also added revised standardized nondiscrimination language to three newly renewed and required hospital notices to beneficiaries.
1. PECOS REDESIGN
The PECOS redesign (PECOS 2.0) aims to simplify provider and supplier enrollment in several ways:
- Applicants will be able to enroll in multiple states or update information across multiple enrollments with a single application.
- PECOS 2.0 will use pre-existing information to complete enrollments faster.
- The enrollment application will adapt based on the application reason.
- More efficient management of group members with the easy addition and removal of members as well as the option to download the complete list of group members.
- An easier revalidation process with reminders for renewal due dates and more clear signposting of information that the applicant needs to review and confirm.
- More rapid application processing through a smart error-checking feature that will validate information throughout the application process.
- Real-time status checking for submitted applications in one view.
According to the published PECOS FAQs, the redesign should not interrupt PECOS availability for an extended period of time and PECOS users can expect access to a robust Knowledge Base interface that will teach users how to navigate PECOS 2.0. Login information, current Medicare Administrative Contractors and current data in PECOS will remain the same and transfer to PECOS 2.0. Records transferred from the existing PECOS to PECOS 2.0 will be noted as such to make them easily identifiable. Applications that were previously closed in PECOS will be available in PECOS 2.0 but will include only limited information. It is unclear at this time what information will and will not transfer over from previously closed applications.
CMS expects to launch PECOS 2.0 in June 2023 and will provide regular updates on the PECOS redesign over the coming months through Medicare Learning Network® announcements.
2. CONSISTENT ENROLLMENT INFORMATION UNDER TIN
In a push to ensure consistency in provider and supplier ownership information in Medicare enrollment records under a single TIN, CMS will send a letter to each provider or supplier that has inconsistent ownership information. The letter will explain that CMS will apply the ownership information from the most recent Medicare enrollment application with an ownership change to all of the enrollment records registered under the provider or supplier’s TIN. If the information in the letter from CMS is correct, then the provider or supplier does not need to do anything further. If the information in the letter from CMS is incorrect, then the provider or supplier must update each of its individual enrollments. Going forward, CMS will apply owner changes to all enrollment records under a particular TIN.
This push for consistency in enrollment information together with the PECOS redesign aligns with CMS’s efforts to promote and practice data transparency, including making enrollment data, such as ownership information, public and subject to increased CMS—as well as third-party—review and scrutiny.
3. UPDATE TO BENEFICIARY NOTICES INITIATIVE
The CMS Office of Management and Budget approved the following hospital-required notices and instructions for renewal:
- Important Message from Medicare, Form CMS 10065
- Detailed Notice of Discharge, Form CMS 10066
- Medicare Outpatient Observation Notice, Form CMS-10611
In their renewed iteration, CMS added revised standardized nondiscrimination language and kept all other information the same. More specifically, the notices listed above have been updated with the addition of the following statement: “You have the right to get Medicare information in an accessible format, like large print, Braille, or audio. You also have the right to file a complaint if you feel you’ve been discriminated against. Visit Medicare.gov/about-us/accessibility-nondiscrimination-notice or call 1-800-MEDICARE (1-800-633-4227) for more information. TTY users can call 1-877-486-2048.” This updated language supports transparency in beneficiary rights and protections and furthers CMS’s efforts to reduce beneficiary confusion regarding admission, discharge and observation status.
These three updated notices and instructions can be found on the CMS Beneficiary Notices Initiative webpage. Hospitals must use the new forms and instructions starting April 27, 2023.

Health Equity Elevated to a Joint Commission National Patient Safety Goal
ARTICLE / CLIENT ALERT
Health Equity Elevated to a Joint Commission National Patient Safety Goal
January 31, 2023
Read time: 4 min
Starting July 1, 2023, The Joint Commission (TJC) will set health equity as a National Patient Safety Goal for certain TJC-accredited organizations and roll out a new Health Care Equity certification program to recognize and certify other hospitals and critical access hospitals that wish to demonstrate greater efforts in achieving health equity. This places health equity on par with TJC’s other National Patient Safety Goals, such as medication safety and surgical error prevention.
TJC has emphasized the importance of improving health equity as a component of patient safety, and recently, it took efforts to emphasize that importance to its accredited organizations. Effective July 1, 2023, TJC will elevate Leadership Standard 04.03.08 (LD.04.03.08), which became effective January 1, 2023, and addresses healthcare disparities as a quality and safety priority, to a new National Patient Safety Goal 16.01.01 (NPSG.16.01.01) for the following TJC-accredited organizations:
- All critical access hospitals and hospitals
- Ambulatory healthcare organizations that provide primary care within the “Medical Centers” service in the ambulatory healthcare program
- Behavioral healthcare and human services organizations that provide “Addiction Services,” “Eating Disorders Treatment,” “Intellectual Disabilities/Developmental Delays,” “Mental Health Services” and “Primary Physical Health Care Services.”
According to a TJC R3 Report that was published in June 2022, LD.04.03.08 was originally placed in TJC’s Leadership Standard category to highlight that health equity requires commitment, vision, creativity and sustained effort at all levels of leadership within an organization, including the C-suite and the board of directors. Shifting the TJC category from Leadership Standard to National Patient Safety Goal does not necessarily change this view, however, according to the report, TJC considers the latter category to be better fitting since its purpose is to improve patient safety with a focus on significant healthcare problems and specific actions to prevent and solve them. This places health equity on par with other National Patient Safety Goals that aim to reduce the likelihood of patient harm, such as medication safety and surgical error prevention.
The shift in category also comes with some minor modifications to the original elements of performance. While the intent behind the standard and elements remains the same, there is heightened focus on health equity rather than on reducing healthcare disparities.
NPSG.16.01.01 elements of performance will be as follows:
- Identify an individual to lead activities to improve healthcare equity
- Assess the patient’s health-related social needs
- Analyze quality and safety data to identify disparities
- Develop an action plan to improve healthcare equity
- Act when the organization does not meet the goals in its action plan
- Inform key stakeholders about progress to improve healthcare equity.
This development builds upon TJC’s focus on health equity during the COVID-19 era. Per TJC’s health equity website, these Leadership Standards and National Patient Safety Goals are among the first of their kind and will help create a consistent national baseline related to the equitable delivery of care. TJC-accredited and some non-TJC-accredited hospitals and critical access hospitals wishing to demonstrate greater efforts in achieving health equity may be interested in pursuing advanced Health Care Equity certification from TJC. Eligible non-TJC-accredited hospitals and critical access hospitals must comply with applicable federal laws, including the Centers for Medicare and Medicaid Services’ (CMS) Conditions of Participation (CoPs). Effective July 1, 2023, this certification will be available upon demonstration that efforts by hospitals and critical access hospitals provide equitable care, treatment and services. Standards for advanced certification are not yet published but can be requested from TJC. Organizations may pre-apply for certification in early 2023.
As TJC is subject to promulgating standards that align with CMS’s CoPs, we anticipate that TJC health equity standards will align with the 2022 CMS Proposed Rules, implementing and further reinterpreting Section 1557 of the Affordable Care Act, which may be complicated if the Proposed Rules are finalized after these new standards are made effective July 1, 2023.
